Archived Medical News Stories

<< Back to Main Archives Index

RSSArchived Drug Trial News Stories - August 2010

Date Title Comments Rating
2010-08-31 Sangart reports positive data from MP4OX Phase IIa study in trauma patients 1 None
2010-08-31 Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study 0 None
2010-08-31 Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin 0 None
2010-08-31 ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients 0 None
2010-08-31 Data monitoring committee recommends early termination following impressive results of AVERROES study 0 None
2010-08-31 Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux 0 None
2010-08-31 Telmisartan and amlodipine combination therapy helps achieve high BP control/response rates 0 2
2010-08-31 Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment 0 None
2010-08-31 Study: IV ibuprofen decreases pain, morphine use in pre and post-operative orthopedic surgery patients 0 None
2010-08-31 Reduced heparin dose lowers bleeding risk after PCI without increasing risk of ischaemic complications 0 None
2010-08-31 J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events 0 None
2010-08-31 Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study 0 None
2010-08-30 Heparin enoxaparin may provide better outcomes than unfractionated heparin 0 None
2010-08-30 Phase 2 INNOVATE PCI trial results for elinogrel presented 0 None
2010-08-30 Smoked cannabis relieves chronic neuropathic pain 1 None
2010-08-30 BioMarin's BMN-701 receives FDA orphan drug designation for treatment of Pompe disease 0 5
2010-08-30 BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010 0 None
2010-08-30 Trius commences oral torezolid phosphate Phase 3 clinical study for ABSSSI 0 None
2010-08-30 Selective lowering of heart rate reduces risk of death and hospitalization: Study 0 None
2010-08-30 Low doses of n-3 fatty acids do not reduce overall rate of major cardiovascular events 0 None
2010-08-30 RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients 0 None
2010-08-30 Large clinical trial does not confirm benefits of erythropoieitin for first ST-elevation myocardial infarction 0 None
2010-08-30 Boehringer Ingelheim announces sub-analysis result of RE-LY trial 0 None
2010-08-30 ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention 0 None
2010-08-30 Forest Laboratories reveals top-line results from cariprazine Phase II clinical trial for bipolar depression 0 None
2010-08-30 TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients 0 None
2010-08-27 Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera 0 None
2010-08-27 Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene 0 None
2010-08-27 FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer 0 5
2010-08-26 Vanda Pharmaceuticals initiates tasimelteon Phase III clinical trial for Non-24-Hour Sleep Wake Disorder 0 None
2010-08-26 Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule 0 None
2010-08-26 NeoPharm second-quarter net loss decreases to $0.8 million 0 None
2010-08-26 Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF 0 None
2010-08-26 FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis 0 None
2010-08-26 Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published 0 None
2010-08-26 Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma 0 None
2010-08-26 FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL 0 None
2010-08-26 Impax Pharmaceuticals completes enrollment in IPX066 Phase III trial for Parkinson’s disease 0 None
2010-08-26 Nabi receives US patent for treatment and prevention of nicotine addiction with NicVAX conjugate vaccines 0 None
2010-08-26 Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity 0 None
2010-08-25 CHX reports positive results from final pivotal trial of Prevora antibacterial tooth coating for cavity prevention 0 None
2010-08-25 NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera 0 None
2010-08-25 Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010 0 None
2010-08-25 ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial 0 None
2010-08-25 Tranzyme Pharma to present ulimorelin Phase 2 data at NGM Meeting 0 5
2010-08-25 Eisai's Phase III trial of Perampanel for epilepsy shows positive results 0 None
2010-08-24 First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090 0 None
2010-08-24 FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP 0 None
2010-08-24 Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C 0 None
2010-08-24 USPTO grants Taligen patent for TT30 lead product candidate 0 None
2010-08-24 Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC 0 None
2010-08-24 FDA OOPD awards Soligenix $1.2M for orBec Phase 3 study in acute gastrointestinal Graft-versus-Host-Disease 0 None
2010-08-23 Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease 0 5
2010-08-23 InSite Vision initiates Phase 1/2 clinical trial of ISV-303 0 None
2010-08-21 Jazz Pharmaceuticals disappointed with FDA Advisory Committee recommendation for JZP-6 in fibromyalgia 0 3.5
2010-08-21 'Yakult' effective in reducing acute diarrhea in young children: Study 0 None
2010-08-20 Protalex initiates dosing in multicenter PRTX-100 Phase 1b clinical study in RA 0 None
2010-08-20 Knopp Neurosciences enters $345 million worldwide licensing agreement with Biogen Idec 0 3
2010-08-20 Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment 0 None
2010-08-20 SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program 0 None
2010-08-20 Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug 0 None
2010-08-20 Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer 0 None
2010-08-20 Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa 0 None
2010-08-20 FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD 0 None
2010-08-19 Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study 0 None
2010-08-19 FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer 0 None
2010-08-18 Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS 0 None
2010-08-18 Rush University Medical Center tests new drug therapy for West Nile fever 0 None
2010-08-18 Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease 0 None
2010-08-18 Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate 0 4
2010-08-18 Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002 0 None
2010-08-18 Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols 0 None
2010-08-18 USPTO grants Neogenix Oncology patent for DNAs encoding novel molecular aspects of NPC-1 antibody 0 None
2010-08-18 AMT's MAA for LPLD gene therapy product Glybera on schedule 0 None
2010-08-18 Lilly to halt development of potential Alzheimer's disease drug semagacestat 0 None
2010-08-18 Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology 0 None
2010-08-18 BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients 0 None
2010-08-17 Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction 0 None
2010-08-17 Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN 0 None
2010-08-17 Hospitals save $284 million through Premier's Quality Connect quality improvement program 0 None
2010-08-17 Intercell reports significant increase in second quarter revenue 0 None
2010-08-17 Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC 0 5
2010-08-17 Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults 0 None
2010-08-17 Oral contraceptives equally effective for obese women 0 None
2010-08-17 Antidepressant alleviates depression in peri- and postmenopausal women: Study 0 None
2010-08-16 Emisphere second-quarter net loss increases to $13.7 million 0 None
2010-08-16 Liverpool scientists create new drug for malaria 0 4
2010-08-16 Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma 0 None
2010-08-16 Titan Pharmaceuticals second-quarter net loss increases to $1.84 million 0 None
2010-08-16 NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies 0 None
2010-08-16 NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention 0 None
2010-08-16 Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009 0 None
2010-08-16 Belatacept study data to be presented at 23rd International Congress of The Transplantation Society 0 None
2010-08-13 CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial 0 None
2010-08-13 Achillion second-quarter net loss increases to $6.4 million 0 None
2010-08-13 Humanetics Corporation secures license to provide treatment for ionizing radiation exposure 0 None
2010-08-13 Neurologix second-quarter net loss increases to $4.5 million 0 4
2010-08-13 NovaBay second-quarter net loss increases to $1.2 million 0 None
2010-08-13 Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer 0 None
2010-08-13 BioSante second-quarter net loss increases to $10.8 million 0 None
2010-08-13 CPF urges people to consider clinical trials for pulmonary fibrosis 0 None
2010-08-13 Study finds Olaparib can reduce tumor size in ovarian cancer women 0 5
2010-08-13 OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009 0 None
2010-08-13 Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma 0 None
2010-08-13 Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals 0 None
2010-08-13 Arrowhead third-quarter 2010 net loss decreases to $0.4 million 0 None
2010-08-13 Antares Pharma second-quarter total revenue increases 78% to $3.1 million 0 None
2010-08-12 FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients 0 None
2010-08-12 Aeterna Zentaris second-quarter revenues decrease to $5.6 million 0 None
2010-08-12 FDA grants BioMimetic Therapeutics orphan drug designation for rhPDGF-BB in treatment of OCD 0 None
2010-08-12 AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma 0 None
2010-08-12 Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement 0 None
2010-08-12 Early administration of TXA reduces death from bleeding without increase in complications: Study 0 None
2010-08-12 FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine 0 None
2010-08-12 Syndax raises $6 million to support ENCORE 301 study in breast cancer 0 None
2010-08-12 Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer 0 None
2010-08-11 HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies 0 5
2010-08-11 PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints 0 None
2010-08-11 Agile initiates Phase 3 NEW CHOICE Study of AG200-15 contraceptive patch 0 None
2010-08-11 Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes 0 None
2010-08-11 OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients 0 None
2010-08-11 Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma 0 None
2010-08-11 Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache 0 None
2010-08-11 FDA clears Curemark's CM – 4612 IND for Phase III clinical trial in ADHD 0 None
2010-08-11 TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug 0 2
2010-08-11 NIAID launches clinical trials of dengue vaccine 0 None
2010-08-11 Omeros net loss for second-quarter 2010 increases to $7.8 million 0 None
2010-08-10 Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C 0 5
2010-08-10 China Pharma second-quarter revenue increases 22% to $16.6 million 0 None
2010-08-10 Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels 0 None
2010-08-10 Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting 0 None
2010-08-10 Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million 0 None
2010-08-10 Pharmasset third-quarter net loss increases to $16.0 million 0 None
2010-08-10 Synta second-quarter net loss increases to $9.1 million 0 3
2010-08-10 Array BioPharma fiscal 2010 revenue increases to $53.9 million 0 None
2010-08-10 Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease 0 None
2010-08-10 Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011 0 None
2010-08-10 NIH begins human clinical testing for dengue virus vaccine 0 None
2010-08-10 Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial 0 None
2010-08-10 ACADIA second-quarter net loss decreases to $4.3 million 0 None
2010-08-10 Poniard second-quarter net loss decreases to $6.5 million 0 None
2010-08-09 Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer 0 None
2010-08-09 Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year 0 None
2010-08-09 Isis second-quarter pro forma net operating loss increases to $15.5 million 0 None
2010-08-09 Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine 0 5
2010-08-09 Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars 0 None
2010-08-09 Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada 0 4.5
2010-08-09 Clinical Data first-quarter gross revenue increases 52% to $6.2 million 0 None
2010-08-09 Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer 0 None
2010-08-09 GTx second-quarter net loss increases to $12.9 million 0 None
2010-08-09 Anti-viral drug addition to standard treatment regimen increases cure rate for hepatitis C 0 None
2010-08-07 Ironwood provides investor update for second-quarter 2010 0 None
2010-08-07 EpiCept second-quarter net loss decreases to $4.9 million 0 None
2010-08-07 Ardea Biosciences second-quarter total revenues decline to $3.5 million 0 None
2010-08-07 Orexigen second-quarter net loss decreases to $11.9 million 0 None
2010-08-07 Halozyme second-quarter revenue increases to $3.2 million 0 None
2010-08-07 Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone 0 None
2010-08-07 U.S. Senate passes I-ACT to enable patients with rare disease to participate in clinical trials 0 None
2010-08-07 NeurogesX net loss for second-quarter 2010 increases to $10.2 million 0 None
2010-08-07 Cyclacel second-quarter net loss decreases to $6.5 million 0 None
2010-08-07 Catalyst announces $1.5 million registered direct offering 0 None
2010-08-06 Cornerstone Pharmaceuticals includes Mary Crowley Research Centers in CPI-613 clinical trials 0 None
2010-08-06 V-101 shows safety profile in treating erythema of rosacea: Clinical study 0 None
2010-08-06 Dyax announces first Phase 3 trial results of KALBITOR for acute HAE 0 None
2010-08-06 Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study 0 None
2010-08-06 TEMPO study recommends early administration of Azilect in PD patients 0 4
2010-08-05 Ligand second-quarter net loss reduces to $0.3 million 0 None
2010-08-05 Biovail second-quarter total revenues increase 23% to $238.8 million 0 None
2010-08-05 Incyte second-quarter total revenues increase to $49.8 million 0 None
2010-08-05 YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis 0 None
2010-08-05 Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million 0 None
2010-08-05 Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer 0 None
2010-08-05 Micromet second-quarter 2010 total revenues increase to $6.5 million 0 None
2010-08-05 Inspire second-quarter total revenue increases 18% to $27.3 million 0 None
2010-08-05 BioCryst second-quarter total revenues increase to $7.6 million 0 None
2010-08-05 CEL-SCI produces and fills first lot of Multikine 0 5
2010-08-05 Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients 0 None
2010-08-05 Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint 1 3
2010-08-05 CTI second-quarter total net operating expenses decrease to $20.0 million 0 None
2010-08-05 ARIAD reports $159.3 million second-quarter net income 0 None
2010-08-05 Genzyme, Isis announce results of two mipomersen phase 3 studies 0 None
2010-08-05 Alnylam second-quarter revenues increase to $26.6 million 0 None
2010-08-05 ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million 0 None
2010-08-05 Anthera second-quarter total operating expenses increase to $7.9 million 0 None
2010-08-05 FDA issues Lux Biosciences Complete Response letter for Luveniq NDA 0 None
2010-08-05 Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation 0 1
2010-08-04 Infinity reports $18.4 million total revenue for second-quarter 2010 0 None
2010-08-04 NCI panel recommends Celsion's Phase III ThermoDox HEAT Study as Priority Clinical Trial for HCC 0 1
2010-08-04 Contrave added to diet and exercise regimen can induce significant weight loss 0 1
2010-08-04 Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine 0 None
2010-08-04 Advaxis receives India’s DCGI approval for ADXS11-001 Phase II clinical trial for cervical cancer 0 None
2010-08-04 Glycotope receives German, Italian regulatory approval for CetuGEX Phase I study for solid cancers 0 None
2010-08-04 CTI files SPA with FDA for new pixantrone phase III trial in relapsed or refractory aggressive B-Cell NHL 0 None
2010-08-04 ZymoGenetics second-quarter net loss declines to $3.8 million 0 None
2010-08-04 Excaliard reports positive results from EXC 001 Phase 2 clinical trial for reducing scar severity 0 None
2010-08-03 Titan completes 60% enrollment in confirmatory Phase 3 clinical study of Probuphine for opioid addiction 0 None
2010-08-03 Vical second-quarter revenues decrease to $2.1 million 0 None
2010-08-03 First patient treated in Phase Ib expansion study of CUDC-101 0 None
2010-08-03 NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM 0 None
2010-08-03 Researchers call for more public disclosure about clinical drug trials 0 None
2010-08-03 Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma 0 5
2010-08-03 ArQule, Daiichi Sankyo announce decision to advance ARQ 197 into Phase 3 clinical trial for NSCLC 0 None
2010-08-03 FDA approves N30 Pharma's NDA for N6022 GSNOR 0 None
2010-08-03 Methods to boost neutralizing antibody may prevent HIV-1 transmission 0 None
2010-08-03 Idera announces $15 million registered direct offering 0 None
2010-08-03 Etoricoxib better than opioid drug tramadol for postoperative pain: Study 0 None
2010-08-03 BioMarin provides update on PEG-PAL Phase 2 clinical study for phenylketonuria 0 5
2010-08-03 BioMarin reports $0.5 million GAAP net loss for second-quarter 2010 0 None
2010-08-03 BioMarin completes BMN 195 Phase 1 clinical trial for Duchenne muscular dystrophy 0 None
2010-08-02 Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF 0 5
2010-08-02 Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research 0 None
2010-08-02 Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity 0 None
2010-08-02 HDL does not predict heart attack risk after dramatic statin therapy: Study 0 None

Total

213 posts
3 comments
30 raters